Patent 11919934 was granted and assigned to Synthorx on March, 2024 by the United States Patent and Trademark Office.
Disclosed herein are interleukin (IL) 15 conjugates and use in the treatment of one or more indications. Also described herein include pharmaceutical compositions and kits comprising one or more of IL-15 conjugates.